U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H24N4O3
Molecular Weight 404.4617
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OZANIMOD

SMILES

CC(C)OC1=CC=C(C=C1C#N)C2=NC(=NO2)C3=C4CC[C@H](NCCO)C4=CC=C3

InChI

InChIKey=XRVDGNKRPOAQTN-FQEVSTJZSA-N
InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1

HIDE SMILES / InChI

Description

Ozanimod (previously known as RPC-1063) is a selective immune-inflammatory modulator of the G protein-coupled receptors sphingosine 1-phosphate 1 and 5, which are part of the sphingosine 1-phosphate (S1P) receptor family. Treatment with S1P receptor modulators interferes with S1P signaling and blocks the response of lymphocytes (a type of white blood cell) to exit signals from the lymph nodes, sequestering them within the nodes. The result is a downward modulation of circulating lymphocytes and anti-inflammatory activity by inhibiting cell migration to sites of inflammation. Ozanimod is currently in phase III clinical trials for the treatment of relapsing multiple sclerosis (RMS) and ulcerative colitis, and also in phase II clinical trials to determine whether it is effective in the treatment of Crohn's disease.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
2016 Jun
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
2016 May 5
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Multiple Sclerosis: 1 mg RPC1063 (Ozanimod) oral capsule daily
Route of Administration: Oral
In Vitro Use Guide
Ozanimod (RPC1063) is a specific agonist for sphingosine-1-phosphate receptor subtypes 1 (S1P1) and S1P5 receptors. The EC50 values were 0.16 nM and 0.41 nM for S1P1 receptors in the inhibition of cAMP generation and [35S]-GTPγS binding. The 83% Emax value of ozanimod against S1P5 receptor was 11 nM. RPC1063 demonstrated a dose‐dependent effect on S1P1 receptor re‐expression on the cell surface, with near complete and sustained loss of cell surface receptor expression at concentrations above 10 nM in S1P1 receptor-HEK293T cells after 1 h incubation.
Name Type Language
OZANIMOD
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
OZANIMOD [WHO-DD]
Common Name English
RPC-1063
Code English
BENZONITRILE, 5-(3-((1S)-2,3-DIHYDRO-1-((2-HYDROXYETHYL)AMINO)-1H-INDEN-4-YL)-1,2,4-OXADIAZOL-5-YL)-2-(1-METHYLETHOXY)-
Systematic Name English
OZANIMOD [USAN]
Common Name English
OZANIMOD [INN]
Common Name English
RPC1063
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 499515
Created by admin on Mon Oct 21 22:49:10 UTC 2019 , Edited by admin on Mon Oct 21 22:49:10 UTC 2019
WHO-ATC L04AA38
Created by admin on Mon Oct 21 22:49:10 UTC 2019 , Edited by admin on Mon Oct 21 22:49:10 UTC 2019
FDA ORPHAN DRUG 611517
Created by admin on Mon Oct 21 22:49:10 UTC 2019 , Edited by admin on Mon Oct 21 22:49:10 UTC 2019
Code System Code Type Description
PUBCHEM
52938427
Created by admin on Mon Oct 21 22:49:10 UTC 2019 , Edited by admin on Mon Oct 21 22:49:10 UTC 2019
PRIMARY
INN
10057
Created by admin on Mon Oct 21 22:49:10 UTC 2019 , Edited by admin on Mon Oct 21 22:49:10 UTC 2019
PRIMARY
EVMPD
SUB181335
Created by admin on Mon Oct 21 22:49:10 UTC 2019 , Edited by admin on Mon Oct 21 22:49:10 UTC 2019
PRIMARY
CAS
1306760-87-1
Created by admin on Mon Oct 21 22:49:10 UTC 2019 , Edited by admin on Mon Oct 21 22:49:10 UTC 2019
PRIMARY